2,742 Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by UNIVEST FINANCIAL Corp

UNIVEST FINANCIAL Corp reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 21.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,330 shares of the biopharmaceutical company’s stock after selling 2,742 shares during the period. UNIVEST FINANCIAL Corp’s holdings in Regeneron Pharmaceuticals were worth $7,833,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $5,682,636,000. State Street Corp raised its position in shares of Regeneron Pharmaceuticals by 3.6% in the 2nd quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock worth $3,014,621,000 after acquiring an additional 170,210 shares in the last quarter. Bank of America Corp DE raised its position in shares of Regeneron Pharmaceuticals by 2.8% in the 1st quarter. Bank of America Corp DE now owns 1,189,584 shares of the biopharmaceutical company’s stock worth $919,120,000 after acquiring an additional 32,158 shares in the last quarter. Amundi raised its position in shares of Regeneron Pharmaceuticals by 27.5% in the 1st quarter. Amundi now owns 1,009,798 shares of the biopharmaceutical company’s stock worth $780,210,000 after acquiring an additional 217,892 shares in the last quarter. Finally, Legal & General Group Plc purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $473,872,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, insider Andrew Murphy sold 4,147 shares of the business’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the sale, the insider directly owned 47,833 shares of the company’s stock, valued at approximately $36,960,559.10. The trade was a 7.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Joseph Larosa sold 4,466 shares of the business’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $965.49, for a total value of $4,311,878.34. Following the completion of the sale, the executive vice president directly owned 38,906 shares in the company, valued at $37,563,353.94. This trade represents a 10.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 27,028 shares of company stock valued at $25,025,950 in the last ninety days. Corporate insiders own 6.97% of the company’s stock.

Key Regeneron Pharmaceuticals News

Investors following REGN have been watching these news items:

• Positive Sentiment: Regeneron collaborator Alnylam reported first-in-human results for CIDEBsiRNA in patients with metabolic-dysfunction-associated steatotic liver disease (MASLD). A single dose rapidly normalized liver fat and improved markers of liver injury, providing encouraging early evidence for a potential treatment opportunity. Article: Alnylam collaborator Regeneron advances CIDEBsiRNA with promising first-in-human results
• Positive Sentiment: Soleo Health was selected as a specialty-pharmacy partner for Pasatru (garetosmab), Regeneron’s recently approved treatment for adults with the rare disorder fibrodysplasia ossificans progressiva. The partnership may support the drug’s distribution and patient access, although no sales impact was specified. Article: Soleo Health selected as a specialty pharmacy partner for Pasatru
• Neutral Sentiment: A Zacks article characterized REGN as a long-term value stock, but the summary provided no new company-specific developments or valuation details that would clearly explain near-term trading. Article: Why Regeneron is a top value stock for the long term

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. TD Cowen lifted their price target on Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the company a “buy” rating in a research report on Wednesday, October 21st. Argus raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 price target on the stock in a research note on Thursday, October 1st. Robert W. Baird increased their price objective on Regeneron Pharmaceuticals from $761.00 to $875.00 and gave the stock a “neutral” rating in a report on Monday, November 2nd. UBS Group raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the company from $660.00 to $978.00 in a research report on Thursday, October 15th. Finally, Cantor Fitzgerald boosted their target price on shares of Regeneron Pharmaceuticals from $795.00 to $980.00 and gave the company an “overweight” rating in a report on Monday, November 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $898.97.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $959.41 on Thursday. The company has a 50 day simple moving average of $811.95 and a two-hundred day simple moving average of $745.49. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $591.52 and a fifty-two week high of $991.73. The company has a market capitalization of $99.25 billion, a price-to-earnings ratio of 21.18, a P/E/G ratio of 1.21 and a beta of 0.10. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.35.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping analysts’ consensus estimates of $16.51 by $3.56. The firm had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The business’s revenue for the quarter was up 36.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $11.83 EPS. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 58.26 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be paid a dividend of $0.94 per share. The ex-dividend date is Friday, November 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. Regeneron Pharmaceuticals’s payout ratio is presently 8.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.